QUESTION	ANSWER
What is the **YORVIPATH® lactation study**?	The **YORVIPATH® lactation study** is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.[1]
What is the study population of the **YORVIPATH® lactation study**?	In the **YORVIPATH® lactation study**, eligible females will be actively recruited from the US participants in the pregnancy registry. Females in the US who want to participate in the lactation study must first enroll in the pregnancy registry and meet the lactation study eligibility criteria study to participate. Females may self enroll into the study or may be enrolled by their healthcare provider (HCP).[1]
What is the treatment in the **YORVIPATH® lactation study**?	In the **YORVIPATH® lactation study**, participants will receive palopegteriparatide prescribed as per normal clinical practice.[1]
What is the study duration of the **YORVIPATH® lactation study**?	Participants will be monitored for 6 days while receiving palopegteriparatide prescribed as per normal clinical practice.[1]
What are the objectives of the **YORVIPATH® lactation study**?	The primary purpose of the **YORVIPATH® lactation study** is to evaluate the transfer of palopegteriparatide into human breast milk of lactating female participants who are breastfeeding while being treated with YORVIPATH.[1]
What is eligibility criteria needed to participate in the **YORVIPATH® lactation study**?	**Inclusion Criteria**[1] Lactating female participants 18 years of age or older treated with YORVIPATH as part of their usual medical care and who have chosen to breastfeed. Note: The participant must have been taking YORVIPATH for a minimum of 14 days prior to sample collection. The major source of infant nutrition must be breast milk (Note: Only one supplemental bottle of no more than 8 oz of formula per day will be allowed during the 14 days before start of the study). Daily dose of YORVIPATH administered within the last 14 days has been stable. Participants recruited from other sources must enroll in the Pregnancy Registry before being allowed to participate in the Lactation Study. Written consent or eConsent obtained. **Exclusion Criteria**[1] 1. Presence of any medical condition that, in the opinion of the investigator, may impair the ability to breastfeed during this study, including but not limited to mastitis and nipple malformation
What are the expected timelines (study start, primary completion, study completion) for the **YORVIPATH® lactation study**?	The estimated study start date for the **YORVIPATH® lactation study** is January 2026.[1] The estimated primary completion date for the **YORVIPATH® lactation study** is January 2028.[1] The estimated study completion date for the **YORVIPATH® lactation study** is January 2028.[1]
Who should I contact for information on enrollment, referrals, or study locations regarding the **YORVIPATH® lactation study**?	For questions about participating in the **YORVIPATH® lactation study** or to inquire about study locations, please email yorvipathlactation@ubc.com or call 877-229-2184 for more information.[1]

1. A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide). ClinicalTrials.gov identifier: NCT07264634. Updated December 4, 2025. Accessed December 4, 2025, https://clinicaltrials.gov/study/NCT07264634?term=NCT07264634&rank=1